Actively Recruiting
Conversion or Neoadjuvant Therapy in Hepatocellular Carcinoma
Led by Guangxi Medical University · Updated on 2026-01-14
2000
Participants Needed
1
Research Sites
417 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This multicenter retrospective study which included patients with hepatocellular carcinoma (HCC) who received conversion or neoadjuvant therapy to explore the best treatment options and the best benefit group.
CONDITIONS
Official Title
Conversion or Neoadjuvant Therapy in Hepatocellular Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically or clinically confirmed diagnosis of hepatocellular carcinoma (HCC)
You will not qualify if you...
- Other malignancies diagnosed within the last 5 years
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Jian-Hong Zhong
Nanning, China, China, 530021
Actively Recruiting
Research Team
J
Jian-Hong Zhong, Ph.D
CONTACT
L
Liang Ma, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here